Zika Virus Vaccine: The Current State of Affairs and Challenges Posed by Antibody-Dependent Enhancement Reaction.
Viral Immunol
; 35(9): 586-596, 2022 11.
Article
in English
| MEDLINE | ID: covidwho-2313628
ABSTRACT
Infection caused by the Zika virus (ZIKV) can lead to serious neurological complications such as microcephaly in neonates. At present, no approved ZIKV vaccine is available, but few vaccine candidates are undergoing clinical trial. One major challenge faced is antibody-dependent enhancement (ADE) reaction that may provoke severe outcome in subsequent infection by ZIKV or other flaviviruses. Thus, more efforts should be dedicated to understanding ADE in designing a safe and effective vaccine to minimize the consequence of the potentially fatal infection's complications and to tackle potential ZIKV reemergence. This review discusses different types of ZIKV vaccine candidates that are currently underway in various stages of preclinical and clinical evaluations.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Viral Vaccines
/
Zika Virus
/
Zika Virus Infection
Type of study:
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
Topics:
Vaccines
Limits:
Humans
/
Infant, Newborn
Language:
English
Journal:
Viral Immunol
Journal subject:
Allergy and Immunology
/
Virology
Year:
2022
Document Type:
Article
Affiliation country:
Vim.2022.0082
Similar
MEDLINE
...
LILACS
LIS